Liquid biopsies

Klaus Pantel & Caroline Dive

December 2016

Tumour components are released into the blood stream by most early and advanced-stage cancers. As such, circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), exosomes and microRNAs (miRNAs) hold potential for minimally invasive and serial testing — especially when conventional biopsy sampling is not feasible — and their potential as tools for prognostication, prediction, and monitoring of response to therapy is currently being investigated. However, the isolation of CTCs and exosomes, as well as the detection of mutations from plasma-derived ctDNA, present a number of technical challenges. In this poster, Klaus Pantel and Caroline Dive highlight the emerging developments in the detection and analysis of circulating tumour material, and its use in 'liquid biopsies' at different stages of tumour evolution.

This poster was produced with financial support from Menarini Silicon Biosystems, Inc.

Extra navigation

Produced with support from